07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

Velafermin: Development discontinued

CRGN discontinued development of velafermin after the compound failed to significantly decrease the incidence of severe mucositis vs. placebo, the primary endpoint, in a Phase II trial. The double-blind, U.S. study enrolled 390 bone marrow...
07:00 , Oct 15, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/12 cls Alnylam (ALNY) Piper Jaffray Edward Tenthoff Downgrade Market perform (from market outperform) 3% $35.43 Tenthoff thinks positive Phase IIa results for ALNY's...
07:00 , Oct 15, 2007 |  BioCentury  |  Finance

Ebb & Flow

Profit-taking by investors after its IPO lock-up expired may have been behind last week's share price dip for cancer and autoimmune company Synta (SNTA), which shed $2.24 (20%) to $8.76 despite announcing a potentially blockbuster...
01:10 , Oct 12, 2007 |  BC Extra  |  Clinical News

CuraGen dropping velafermin

CRGN discontinued development of velafermin after the human fibroblast growth factor 20 ( FGF-20 ) failed to significantly decrease the incidence of severe mucositis vs. placebo, the primary endpoint, in a Phase II trial to...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Clinical News

Velafermin: Completed Phase II enrollment

CRGN completed enrollment of 390 patients in a double-blind, placebo-controlled, U.S. Phase II trial. CuraGen Corp. (CRGN), Branford, Conn.   Product: Velafermin (CG53135)   Business: Other   Molecular target: Fibroblast growth factor (FGF)   Description:...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Company News

CuraGen cancer, other news

CRGN said it will reduce its headcount by about 40 (44%) to about 50 and close its pilot manufacturing plant. The company said the cuts would mainly be composed of preclinical and manufacturing researchers. In...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

CuraGen, Roche deal

ROG will acquire CRGN’s 454 Life Sciences Corp. subsidiary for $140 million in cash. In addition, 454 shareholders may receive up to $14.9 million from the exercise of stock options in the private company. ROG...
07:00 , Apr 2, 2007 |  BioCentury  |  Finance

Ebb & Flow

At the beginning of this year, SkyePharma (LSE:SKP; SKYE) laid out three goals it wanted to meet in 2007: complete a restructuring of its royalty financing with Paul Capital, divest its injectable business and complete...
01:11 , Mar 30, 2007 |  BC Extra  |  Company News

Roche to acquire Curagen's 454

Roche (SWX:ROG) will acquire CRGN's high throughput genome sequencing subsidiary 454 Life Sciences for $140 million in cash. In addition, 454 shareholders may receive up to $14.9 million from the exercise of stock options. ROG...
07:00 , Jun 5, 2006 |  BC Week In Review  |  Clinical News

Velafermin: Phase II started

CRGN began a double-blind, placebo-controlled, U.S. phase II trial in about 400 patients. CuraGen Corp. (CRGN), Banford, Conn.   Product: Velafermin (CG53135)   Business: Other   Molecular target: Fibroblast growth factor (FGF)   Description: Human...